Company Information

Learn More About XBRL  

Address: 6300 DUMBARTON CIRCLE  
City: FREMONT 
State: CA 
Zip Code: 94555 
Telephone: (510) 585-2200 


Description of Business


Primary SIC Code: 2834
(As filed with the SEC)  

ARYx Therapeutics, Inc., or ARYx, is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with well-established, commercially successful drugs. We use our RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of these original drugs but are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these compounds.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2010-0.83NAN/E
03/2010-1.07NAN/E
12/2009-1.21NAN/E
09/2009-1.62NAN/E
06/2009-1.14NAN/E
03/2009-1.47NAN/E
12/2008-1.65NAN/E
09/20088.48NA0.72

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2009 Leverage 2009
Net Inc/Comm Equity-0.18Total Liab/Total Assets1.24
Net Inc/Total Assets-2.67Total Liab/Inv Cap-13.62
Net Inc/Inv Cap29.48Total Liab/Comm Equity0.08
Pretax Inc/Net SalesNAInterest Coverage Ratio-15.53
Net Inc/Net SalesNACurr Debt/Equity-1.66
Cash Flow/Net SalesNALTD/Equity-1.81
SG&A/NetSalesNATotal Debt/Equity-3.47
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio1.01
Inventory TurnoverNACurrent Ratio1.01
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  6/30/2010 3/31/2010 12/31/2009 9/30/2009
Total Revenues(Net Sales) 0.00 0.00 0.00 0.00
Cost of Goods Sold NA NA 0.00 0.00
Selling & Admin Exps 2.24 3.78 2.34 2.64
Operating Income -3.24 -6.02 -5.32 -7.63
Interest Exp 0.39 0.43 0.49 0.52
Pretax Income -3.64 -6.39 -5.79 -8.15
Other Income -0.01 0.06 0.03 0.00
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -3.64 -6.39 -5.79 -8.15

Balance Sheet (Millions)

Assets 6/30/2010 3/31/2010 12/31/2009 9/30/2009
Cash & Short Term Investments 1.55 6.45 7.91 14.34
Receivables - Total 0.59 0.62 NA 0.57
Inventories - Total NA NA NA NA
Total Current Assets 2.19 7.27 8.81 15.10
Net Property, Plant & Equipment 1.78 2.01 2.26 2.47
Total Assets 5.02 10.58 12.41 19.29
Liabilities        
Accounts Payable 2.82 3.14 3.50 3.16
Debt in Current Liabilities 3.34 4.10 4.85 6.79
Total Current Liabilities 6.15 7.25 8.68 9.95
Long-Term Debt 3.56 4.44 5.28 6.37
Total Liabilities 10.95 12.98 15.32 17.47
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA 0.00 NA
Common Stock 0.03 0.03 0.03 0.03
Retained Earnings -197.14 -193.50 -187.11 -181.32
Treasury Stock NA NA NA NA
Total Stockholders' Equity -5.93 -2.40 -2.92 1.82
Total Liabilities and Stockholders' Equity 5.02 10.58 12.41 19.29

Cash Flow Summary (Millions)

Categories 6/30/2010 3/31/2010 12/31/2009 9/30/2009
Net Cash Provided by Operating Activities -3.52 -6.42 -6.09 -6.79
Net Cash Provided by Investing Activities 0.20 0.37 7.27 3.08
Net Cash Provided by Financing Activities -1.58 4.94 -0.62 -1.38

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20050.00-27.96--
12/20064.74-27.33--
12/20074.16-27.56-8.24
12/200819.72-31.22-1.65
12/20090.00-33.17-1.21
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/105010,02829.97




Report Date : 8/30/2010

Powered By Edgar Online Copyright 2010, EDGAR Online, Inc. All rights reserved. Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.